FindTrial
Sign In

Clinical efficacy of Autologous Intraovarian Platelet Rich Plasma Treatment in Women With Poor Ovarian Response

Prospective clinical study on ovarian injection of autologous platelet-rich plasma in a population with low ovarian response

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300073156
Enrollment
Unknown
Registered
2023-07-03
Start date
2023-07-15
Completion date
Unknown
Last updated
2023-07-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

poor ovarian response

Interventions

Autologous Intraovarian Platelet Rich Plasma:Autologous Intraovarian Platelet Rich Plasma
Auologous Intraovarian Platelet Rich Plasma :Auologous Intraovarian Platelet Rich Plasma

Sponsors

Affiliated Hospital of Youjiang Medical College for Nationalities
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
38 Years to 45 Years

Inclusion criteria

Inclusion criteria: 1. Willingness to participate and provide written consent prior to initiation of any study-related procedures 2. Indication for IVF or ICSI treatment, Body mass index (BMI) =18 kg/m2 and =38 kg/m2 3. poor ovarian response meets the following criteria: advanced age or high-risk factors with ovarian hyporesponsiveness;Serum AMH < 0.5 -1.1ng/ml ;Antral follicular count (AFC) in both ovaries = 5-7 4. At least 1 ovary must be visible by transvaginal ultrasound examination; ovaries must be judged accessible by transvaginal puncture 5. The subject must be able to communicate well with the investigator and research staff and to comply with the requirements of the study protocol

Exclusion criteria

Exclusion criteria: 1.Pregnancy 2.Genetic causes of premature ovarian failure such as Turner's syndrome or chromosomal abnormalities 3.Basic disease: blood disease, significant thrombocytopenia, diabetes, hypertension, thyroid disease, thrombotic disease, tumor disease, autoimmune disease. 4.Contraindication for transvaginal ovarian puncture (such as previous major lower abdominal surgery and known severe pelvic adhesion) 5.Uterine malformations or pathologies (such as sub mucosal fibroid(s), endometrial hyperplasia, endometrial fluid accumulation, or endometrial adhesions)

Design outcomes

Primary

MeasureTime frame
Number of Metaphase II oocyte yield.;Oocyte quality;Embryo number;Embryo quality;Fertilization rate;—

Secondary

MeasureTime frame
Antral follicle count;Serum anti-mullerian hormone (AMH);Serum follicle stimulating hormone (FSH);Clinical pregnancy rate;Biochemical pregnancy rate;Early abortion rate;—

Countries

China

Contacts

Public ContactHuang qiuyan

Affiliated Hospital of Youjiang Medical College for Nationalities

445642639@qq.com+86 186 7765 8526

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026